{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-221375","form_type":"8-K","ticker":"FDMT","cik":"0001650648","company_name":"4D Molecular Therapeutics, Inc.","filed_at":"2024-09-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.964002+00:00","generated_at":"2026-05-31T03:58:56.780879+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"4D-150 shows up to 98% injection reduction in wet AMD; Phase 3 4FRONT expected Q1 2025","bullets":["Phase 2b Broad (n=30): 89% annualized injection reduction, 80% with 0 or 1 injection, 70% injection-free at 52 weeks.","Phase 2b Recently Diagnosed (n=15): 98% injection reduction, 100% with 0 or 1 injection, 87% injection-free.","Safety: 2.8% rate of 4D-150-related IOI (2 of 71); no hypotony, endophthalmitis, or vasculitis observed.","Planned Phase 3 4FRONT-1 (N=500) to start Q1 2025; primary endpoint noninferiority BCVA vs aflibercept; RMAT and PRIME designations."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-221375","json":"https://secwatch.observer/filing/0001193125-24-221375.json","markdown":"https://secwatch.observer/filing/0001193125-24-221375.md","text":"https://secwatch.observer/filing/0001193125-24-221375.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650648/000119312524221375/0001193125-24-221375-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650648/000119312524221375/d865019d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T03:58:56.780879+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}